IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort : a cross-sectional study

Vijayaprakash Suppiah; Silvana Gaudieri; Nicola J. Armstrong; Kate S. O'Connor; Thomas Berg; Martin Weltman; Maria Lorena Abate; Ulrich Spengler; Margaret Bassendine; Gregory J. Dore; William L. Irving; Elizabeth Powell; Margaret Hellard; Stephen Riordan; Gail Matthews; David Sheridan; Jacob Nattermann; Antonina Smedile; Tobias Muller; Emma Hammond; David Dunn; Francesco Negro; Pierre-Yves Bochud; Simon Mallal; Golo Ahlenstiel; Graeme J. Stewart; Jacob George; David R. Booth

doi:10.1371/journal.pmed.1001092

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort : a cross-sectional study

Vijayaprakash Suppiah, Silvana Gaudieri, Nicola J. Armstrong, Kate S. O'Connor, Thomas Berg, Martin Weltman, Maria Lorena Abate, Ulrich Spengler, Margaret Bassendine, Gregory J. Dore, William L. Irving, Elizabeth Powell, Margaret Hellard, Stephen Riordan, Gail Matthews, David Sheridan, Jacob Nattermann, Antonina Smedile, Tobias Muller, Emma HammondDavid Dunn, Francesco Negro, Pierre-Yves Bochud, Simon Mallal, Golo Ahlenstiel, Graeme J. Stewart, Jacob George, David R. Booth

Research output: Contribution to journal › Article › peer-review

106 Citations (Scopus)

Abstract

Background: To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%-50% of patients. Interleukin 28B (IL28B) genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we studied the combined effect of variants of IL28B with human leukocyte antigen C (HLA-C), and its ligands the killer immunoglobulin-like receptors (KIR), which have previously been implicated in HCV viral control.

Original language	English
Article number	e1001092
Number of pages	8
Journal	PLoS Medicine
Volume	8
Issue number	9
DOIs	https://doi.org/10.1371/journal.pmed.1001092
Publication status	Published - 2011

Open Access - Access Right Statement

©2011 Suppiah et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords

genotyping techniques
hepatitis C virus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pmed.1001092

Cite this

Suppiah, V., Gaudieri, S., Armstrong, N. J., O'Connor, K. S., Berg, T., Weltman, M., Abate, M. L., Spengler, U., Bassendine, M., Dore, G. J., Irving, W. L., Powell, E., Hellard, M., Riordan, S., Matthews, G., Sheridan, D., Nattermann, J., Smedile, A., Muller, T., ... Booth, D. R. (2011). IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort : a cross-sectional study. PLoS Medicine, 8(9), Article e1001092. https://doi.org/10.1371/journal.pmed.1001092

@article{d5b98380f5f14132bd19f404f636a049,

title = "IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort : a cross-sectional study",

abstract = "Background: To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%-50% of patients. Interleukin 28B (IL28B) genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we studied the combined effect of variants of IL28B with human leukocyte antigen C (HLA-C), and its ligands the killer immunoglobulin-like receptors (KIR), which have previously been implicated in HCV viral control.",

keywords = "genotyping techniques, hepatitis C virus",

author = "Vijayaprakash Suppiah and Silvana Gaudieri and Armstrong, {Nicola J.} and O'Connor, {Kate S.} and Thomas Berg and Martin Weltman and Abate, {Maria Lorena} and Ulrich Spengler and Margaret Bassendine and Dore, {Gregory J.} and Irving, {William L.} and Elizabeth Powell and Margaret Hellard and Stephen Riordan and Gail Matthews and David Sheridan and Jacob Nattermann and Antonina Smedile and Tobias Muller and Emma Hammond and David Dunn and Francesco Negro and Pierre-Yves Bochud and Simon Mallal and Golo Ahlenstiel and Stewart, {Graeme J.} and Jacob George and Booth, {David R.}",

year = "2011",

doi = "10.1371/journal.pmed.1001092",

language = "English",

volume = "8",

journal = "PLoS Medicine",

issn = "1549-1277",

publisher = "Public Library of Science",

number = "9",

}

Suppiah, V, Gaudieri, S, Armstrong, NJ, O'Connor, KS, Berg, T, Weltman, M, Abate, ML, Spengler, U, Bassendine, M, Dore, GJ, Irving, WL, Powell, E, Hellard, M, Riordan, S, Matthews, G, Sheridan, D, Nattermann, J, Smedile, A, Muller, T, Hammond, E, Dunn, D, Negro, F, Bochud, P-Y, Mallal, S, Ahlenstiel, G, Stewart, GJ, George, J & Booth, DR 2011, 'IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort : a cross-sectional study', PLoS Medicine, vol. 8, no. 9, e1001092. https://doi.org/10.1371/journal.pmed.1001092

TY - JOUR

T1 - IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort : a cross-sectional study

AU - Suppiah, Vijayaprakash

AU - Gaudieri, Silvana

AU - Armstrong, Nicola J.

AU - O'Connor, Kate S.

AU - Berg, Thomas

AU - Weltman, Martin

AU - Abate, Maria Lorena

AU - Spengler, Ulrich

AU - Bassendine, Margaret

AU - Dore, Gregory J.

AU - Irving, William L.

AU - Powell, Elizabeth

AU - Hellard, Margaret

AU - Riordan, Stephen

AU - Matthews, Gail

AU - Sheridan, David

AU - Nattermann, Jacob

AU - Smedile, Antonina

AU - Muller, Tobias

AU - Hammond, Emma

AU - Dunn, David

AU - Negro, Francesco

AU - Bochud, Pierre-Yves

AU - Mallal, Simon

AU - Ahlenstiel, Golo

AU - Stewart, Graeme J.

AU - George, Jacob

AU - Booth, David R.

PY - 2011

Y1 - 2011

N2 - Background: To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%-50% of patients. Interleukin 28B (IL28B) genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we studied the combined effect of variants of IL28B with human leukocyte antigen C (HLA-C), and its ligands the killer immunoglobulin-like receptors (KIR), which have previously been implicated in HCV viral control.

AB - Background: To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%-50% of patients. Interleukin 28B (IL28B) genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we studied the combined effect of variants of IL28B with human leukocyte antigen C (HLA-C), and its ligands the killer immunoglobulin-like receptors (KIR), which have previously been implicated in HCV viral control.

KW - genotyping techniques

KW - hepatitis C virus

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:41559

U2 - 10.1371/journal.pmed.1001092

DO - 10.1371/journal.pmed.1001092

M3 - Article

C2 - 21931540

SN - 1549-1277

VL - 8

JO - PLoS Medicine

JF - PLoS Medicine

IS - 9

M1 - e1001092

ER -

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort : a cross-sectional study

Abstract

Open Access - Access Right Statement

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this